Edition:
United States

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

27,733.00ZAc
5:53am EDT
Change (% chg)

133.00 (+0.48%)
Prev Close
27,600.00
Open
27,788.00
Day's High
27,788.00
Day's Low
27,507.00
Volume
395,651
Avg. Vol
1,257,267
52-wk High
38,849.00
52-wk Low
25,564.00

Latest Key Developments (Source: Significant Developments)

Aspen says EC to investigate co, European units
Monday, 15 May 2017 06:10am EDT 

May 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::Opening of European Commission proceedings.Confirms European Commission opened proceedings to investigate certain actions of Aspen Holdings, certain of its European subsidiaries.Will work constructively with European Commission in its process.Not currently in a position to comment on these proceedings.  Full Article

Aspen says welcome probe into allegations of anti-competitive behavior
Monday, 24 Apr 2017 02:00am EDT 

April 24 (Reuters) - Aspen ::Notes media reports that competition commission has decided to take up democratic alliance's request to investigate alleged anti-competitive conduct of co in South Africa.Welcomes process and opportunity to categorically set aside such allegations of anti- competitive behavior.Committed to full and constructive engagement with competition commission should it wish to pursue such an investigation.Aspen has not increased pricing of its products outside of this regulatory framework.  Full Article

Aspen to not comment on allegations in press reports
Tuesday, 18 Apr 2017 02:00am EDT 

April 18 (Reuters) - Aspen Pharmacare Holdings Limited ::Aspen’S response to the press reports of 14 and 15 April 2017.Demonstrated commitment to providing medicines affordably over many years, supply of oncology products in question is no exception.Aspen will not comment on these public allegations.Aspen looks forward to opportunity to demonstrate integrity and legality of its practices in context of these legal processes..Oncology portfolio in question generated revenue in EU in Aspen's FY ended 30 June 2016 of EUR 60 million (963 mln rand).  Full Article

Aspen Pharmacare says HY normalised HEPS rose 6 pct to 692 cents
Thursday, 9 Mar 2017 12:30am EST 

Aspen Pharmacare Holdings Ltd : HY revenue for group grew 13% to R19,8 billion and normalised headline earnings per share increased by 6% to 692 cents . Results in second half of 2017 financial year will be influenced by strengthening of rand .Says overall stronger underlying performance in second half of 2017 financial year is anticipated.  Full Article

Aspen Pharmacare sees HEPS for six months to Dec.31 up 49-57 pct
Wednesday, 1 Mar 2017 10:00am EST 

Aspen Pharmacare Holdings Ltd : . Sees six months to dec.31 headline earnings per share up 49 pct to 57 pct , between 624.0 to 657.5 cents .Sees six months to dec.31 nheps up 3 pct to 8 pct, between 675.2 to 707.9.  Full Article

Aspen completes acquisition of a portfolio of anaesthetics with GlaxoSmithKline
Wednesday, 1 Mar 2017 02:00am EST 

Aspen Pharmacare Holdings:Aspen Holdings is pleased to announce that this transaction completed.  Full Article

Aspen Pharmacare says GSK sells remaining stake in co
Thursday, 29 Sep 2016 03:05am EDT 

Aspen Pharmacare Holdings Ltd : GSK completed an accelerated bookbuild for disposal of its remaining shareholding in aspen .Disposal in no way affects ongoing collaboration between aspen and GSK in South Africa.  Full Article

GSK gets 477 mln stg gross proceeds from Aspen Pharmacare stake sale
Thursday, 29 Sep 2016 02:54am EDT 

Glaxosmithkline Plc :Gross proceeds of Aspen transaction are equivalent to £477 million.  Full Article

GSK says to sell remaining stake in Aspen Pharmacare
Wednesday, 28 Sep 2016 11:19am EDT 

GlaxoSmithKline Plc : GSK intends to sell remaining holding in Aspen . Intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd . Offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately .Offering is expected to comprise up to 28.2 million Aspen ordinary shares equivalent to 6.2 pct of Aspen's ordinary share capital.  Full Article

Aspen Pharmacare to buy exclusive rights to commercialise AstraZeneca's anaesthetics portfolio
Thursday, 1 Sep 2016 02:00am EDT 

Aspen Pharmacare Holdings Ltd : Had signed an agreement with AstraZeneca whereby AGI will acquire exclusive rights to commercialise astrazeneca's global (excluding USA) anaesthetics portfolio .Transaction was anticipated to complete during Q1 of Aspen's 2017 financial year.  Full Article

More From Around the Web

Aspen under EU antitrust spotlight over excessive cancer drug prices

BRUSSELS EU antitrust regulators will investigate whether Aspen Pharmacare is charging excessive prices for five key cancer drugs in a move which could lead to a hefty fine for Africa's largest generic drugmaker.